Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | NAMPT | P43490 | 5/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31566060 | 0.89 | POLB (0.49) | CCR2POLBEPHX2ESR1ESR2 | |
| SCHEMBL31566056 | 0.88 | POLB (0.56) | CCR2KCNH2NAMPTPOLBEPHX2 | |
| SCHEMBL31565954 | 0.81 | NAMPT (0.44) | CCR2KCNH2NAMPTSCN9AESR1 | |
| SCHEMBL31566016 | 0.80 | ESR1 (0.47) | CCR2KCNH2NAMPTSCN9ASCN7A | |
| SCHEMBL31565984 | 0.79 | CCR2 (0.44) | CCR2KCNH2NAMPTEPHX2ESR1 | |
| SCHEMBL31566007 | 0.78 | HRH3 (0.57) | CCR2ESR1ESR2 | |
| SCHEMBL31565948 | 0.78 | LIPE (0.48) | SCN9APOLBESR1ESR2 | |
| SCHEMBL3989312 | 0.78 | LIPE (0.48) | KCNH2SCN9ASCN7AESR1ESR2 | |
| SCHEMBL31565963 | 0.77 | ESR1 (0.45) | KCNH2SCN9ASCN7AESR1ESR2 | |
| SCHEMBL31566067 | 0.77 | ABHD6 (0.52) | CCR2SCN9AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129028-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | CCR2 3845/4885KCNH2 3526/4885NAMPT 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.